Novel therapies for severe Clostridium difficile colitis

Current Opinion in Critical Care

Volumn 22, Issue 2, 2016, Pages 167-173

  Waltz, Paul ^a   Zuckerbraun, Brian ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Clostridium difficile infection; colonic lavage; fecal microbiota therapy; fecal transplant

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL TOXIN; CADAZOLID; FIDAXOMICIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL SPORE; BIODIVERSITY; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; DISEASE SEVERITY; FECAL MICROBIOTA TRANSPLANTATION; FECES MICROFLORA; HOSPITAL INFECTION; HUMAN; IMMUNOTHERAPY; INCIDENCE; MICROBIOME; NONTOXIGENIC CLOSTRIDIUM DIFFICILE SPORE; PATHOGENESIS; RECURRENCE RISK; TREATMENT OUTCOME; CLOSTRIDIUM INFECTIONS; COLITIS; DRUG EFFECTS; FLUID THERAPY; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PRACTICE GUIDELINE; PROCEDURES; RECURRENT DISEASE; RISK FACTOR; TRENDS;

ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLITIS; FECAL MICROBIOTA TRANSPLANTATION; FLUID THERAPY; HUMANS; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; RISK FACTORS;

EID: 84960429054     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0000000000000282     Document Type: Article

References (39)

1. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:825-834.
2. Reveles KR, Lee GC, Boyd NK, et al. The rise in Clostridium difficile infection incidence among hospitalized adults in the United States. Am J Infect Control 2014; 42:1028-1032.
3. Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 2013; 173:2039-2046.
4. Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 2008; 190:2505-2512.
5. Carter GP, Chakravorty A, Pham A, et al. Defining the roles of TcdA and TcdB in localized gastrointestinal disease, systemic organ damage, and the host response during Clostridium difficile infections. MBio 2015; 6:1-10.
6. Gerding DN, Johnson S, Rupnik M, et al. Clostridium difficile binary toxin CDT. Gut Microbes 2014; 5:15-27.
7. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015; 372:1539-1548.
8. Shahinas D, Silverman M, Sittler T, et al. Toward an understanding of changes in diversity associated with fecal microbiome transplantation base on 16s rRNA gene deep sequencing. MBio 2012; 3:1-10.
9. Sorg JA, Sonenshein AL. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol 2010; 192:4983-4990.
10. Brandes V, Schelle I, Brinkmann S, et al. Protection from Clostridium difficile toxin B-catalysed Rac1/Cdc42 glucosylation by tauroursodeoxycholic acidinduced Rac1/Cdc42 phosphorylation. Biol Chem 2012; 393:77-84.
11. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108:478-498.
12. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-455.
13. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20 (Suppl 2):1-26.
14. Kim PK, Huh HC, Cohen HW, et al. Intracolonic vancomycin for severe Clostridium difficile colitis. Surg Infect (Larchmt) 2013; 14:532-539.
15. Malamood M, Nellis E, Ehrlich AC, et al. Vancomycin enemas as adjunctive therapy for Clostridium difficile infection. J Clin Med Res 2015; 7:422-427.
16. Cornely O, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a doubleblind, noninferiority, randomised controlled trial. Lancet Infect Dis 2012; 12:281-289.
17. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-431.
18. Cornely O, Nathwani D, Ivanescu C, et al. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother 2014; 69:2892-2900.
19. Nathwani D, Cornely O, Van Engen AK, et al. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother 2014; 69:2901-2912.
20. Louie T, Nord CE, Talbot GH, et al. Multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrob Agents Chemother 2015; 59:6266-6273.
21. Gehin M, Desnica B, Dingemanse J. Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infection. Int J Antimicrob Agents 2015; 46:576-581.
22. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44:854-859.
23. Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415.
24. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015; 41:835-843.
25. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108:500-508.
26. Lagier J-C, Delord M, Million M, et al. Dramatic reduction in Clostridium difficile ribotype 027-associated mortality with early fecal transplantation by the nasogastric route: a preliminary report. Eur J Clin Microbiol Infect Dis 2015; 34:1597-1601.
27. Zainah H, Hassan M, Shiekh-Sroujieh L, et al. Intestinal microbiota transplantation, a simple and effective treatment for severe and refractory Clostridium difficile infection. Dig Dis Sci 2015; 60:181-185.
28. Aroniadis OC, Brandt LJ, Greenberg A, et al. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience. J Clin Gastroenterol 2015. [Epub ahead of print]
29. Agrawal M, Aroniadis OC, Brandt LJ, et al. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol 2015. [Epub ahead of print]
30. Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther 2015; 42:470-476.
31. Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014; 109:1065-1071.
32. Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C difficile infection. JAMA 2015; 313:1719.
33. Shah PJ, Vakil N, Kabakov A. Role of intravenous immune globulin in streptococcal toxic shock syndrome and Clostridium difficile infection. Am J Heal Pharm 2015; 72:1013-1019.
34. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362:197-205.
35. Yang Z, Ramsey J, Hamza T, et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun 2015; 83:822-831.
36. Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014; 59:345-354.
37. Bender KO, Garland M, Ferreyra JA, et al. A small-molecule antivirulence agent for treating Clostridium difficile infection. Sci Transl Med 2015; 7:1-11.
38. Dallas KB, Condren A, Divino CM. Life after colectomy for fulminant Clostridium difficile colitis: a 7-year follow up study. Am J Surg 2014; 207:533-539.
39. Neal MD, Alverdy JC, Hall DE, et al. Diverting loop ileostomy and colonic lavage. Ann Surg 2011; 254:423-429.